US-based data analytics company AiCure and The IMA Group have formed a partnership to optimise clinical trial recruitment and patient engagement.

This year-long collaboration aims to understand patient behaviour and drug compliance outside a clinical trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The IMA Group’s division IMA Clinical Research will equip patients with AiCure’s patient engagement solution ‘Patient Connect’ to study health management outside a trial. This solution is intended to help patients manage their treatment at home.

Sponsors will get access to a diverse pool of patients with known adherence patterns across therapeutic areas that could be recruited for upcoming trials.

AiCure CEO Dr Ed Ikeguchi said: “The success of a clinical trial depends on the quality of its data, which often comes down to how likely a patient is to comply with treatment protocols.

“Understanding that risk and how a patient manages their health in a non-trial setting before recruiting them can make a critical difference in a trial setting.”

Through its partnership with AiCure, the company will start patient engagement and compliance measurement to medications outside of a study setting.

The partnership will also assess compliance to treatment across various conditions, ranging from pain to cardiovascular conditions, CNS diseases, and diabetes.

During a 30-day programme, patients will use AiCure’s solution through their smartphone each time they take a dose.

The solution confirms adherent dosing behavior in a HIPAA compliant manner, using computer vision and AI.

Patient Connect can identify subtle changes in a patient’s condition by aggregating ePRO and digital biomarker data.

Patients will also be able to connect directly to a clinician for further support.

The data collected can be fed into AiCure’s predictive analytics engine, while will enable future sponsors to gain insights about dosing behaviour across various disease states.